ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares of Stock

by · The Markets Daily

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $70.79, for a total transaction of $35,395.00. Following the transaction, the vice president owned 73,924 shares of the company’s stock, valued at $5,233,079.96. This trade represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

  • On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00.
  • On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $81.84, for a total transaction of $40,920.00.

ANI Pharmaceuticals Trading Up 0.3%

Shares of ANIP opened at $70.40 on Tuesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals, Inc. has a 1-year low of $69.58 and a 1-year high of $99.39. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 15.17 and a beta of 0.45. The firm has a 50 day simple moving average of $76.97 and a 200-day simple moving average of $78.17.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The firm had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.ANI Pharmaceuticals’s revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price objective on the stock. Guggenheim lowered their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Canaccord Genuity Group reduced their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $105.57.

Read Our Latest Stock Analysis on ANI Pharmaceuticals

Institutional Trading of ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Penn Capital Management Company LLC boosted its position in shares of ANI Pharmaceuticals by 2,058.9% in the fourth quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock worth $10,858,000 after acquiring an additional 131,030 shares during the last quarter. CenterBook Partners LP acquired a new position in ANI Pharmaceuticals during the fourth quarter worth approximately $1,518,000. Jupiter Topco LLC purchased a new position in ANI Pharmaceuticals during the second quarter worth approximately $6,597,000. NFJ Investment Group LLC purchased a new position in ANI Pharmaceuticals during the second quarter worth approximately $2,766,000. Finally, Walleye Capital LLC acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $8,784,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.

See Also